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Abstract  
Notch is a key player in various developmental processes during the embryonic stage as well as 
in regulating tissue homeostasis, cell differentiation and stem cell maintenance in adult life. 
Activation of Notch signaling occurs following Notch receptor-ligand interaction and subsequent 
enzymatic proteolysis by the gamma-secretase complex, resulting in the cytoplasmic release of 
Notch intracellular domain (NICD) which translocates to the nucleus to initiate the downstream 
transcriptional machinery. Notch activation and its aberrant signaling have been broadly linked 
to the pathogenesis of cancer and some chronic inflammatory diseases resulting in pathologic 
fibrotic processes. This review focuses on the molecular basis of Notch-induced signaling and its 
interaction with other pathways to identify therapeutic targets. We also highlight current efforts 
to pharmacologically intervene in Notch signaling and discuss promising ongoing experimental 
and clinical studies.  
 
 
  
3 
 
1. Introduction. 
Notch signaling was first described a century ago after the discovery of notched (toothed) wings 
in the fruit fly Drosophila melanogaster resulting from a sex-linked mutation in the gene later 
known as Notch.1 Notch signaling plays a critical role in many fundamental processes including 
cell proliferation, apoptosis, activation of differentiation programs and specific cell fates. The 
aberrant gain or loss of function of Notch signaling components has been related to many human 
diseases. The first evidence for the involvement of Notch genes and receptor precursors in cancer 
was reported in T-cell acute lymphoblastic leukemia (T-ALL).2 However, altered signaling of the 
Notch pathway has been linked to numerous diseases, including various cancers, fibrosis and 
degenerative diseases. Notch receptors are type I transmembrane proteins. In order to be 
activated, following the translation of the Notch genes, Notch receptors precursors need several 
steps of glycosylation and an intracellular proteolytic step to be expressed at the cell surface. 
Then, following engagement with their cognate ligands, two sequential proteolytic steps release 
the active intracellular domains of the receptors, which then migrate toward the nucleus to 
perform their transcriptional activity. In particular, the proteolytic steps, involving serine- 
(furins), metallo- (A Disintegrin and Metalloproteinase, ADAMs) and aspartyl (γ-secretase) 
proteases, are necessary to activate the Notch proteins. These proteolytic activities are widely 
expressed in normal and diseased tissues, and their activities are essential to modulate the 
functions of other biological peptides required for the normal homeostasis of cells, tissues and 
organs, as well as in diseases. Thus, for selective therapy, it is mandatory to achieve only 
localized inhibition of these activities, in order to protect the other functions of these enzymes 
and also to maintain essential Notch-dependent signaling pathways in non-target tissues. The 
strategies used initially have been non-specific and associated with detrimental side-effects. 
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More recently, improved selectivity and decreased toxicity have been sought. The design of new 
inhibitors of γ-secretase to achieve blockade of the Notch pathway over other pathways, or the 
development of antibodies directed either against the Notch receptors or Notch ligands, are some 
examples of these recent attempts at selective and specific control of Notch. In this Perspective, 
we provide a brief overview of the importance of Notch signaling in cellular biology by 
describing the main components of Notch signaling, focusing on the unique features of this 
pathway in some pathological conditions. Apart from that we also highlight potential targets for 
pharmacological interventions and some therapeutic strategies to control Notch functions. 
 
1.1. Notch ligand-receptor interaction. 
Canonical Notch signaling (Figure 1).  
Notch signaling is primarily induced by binding of specific ligands from the Delta-like (DLL-1,  
3 and 4) and Jagged (Jagged 1 and Jagged 2) families.3,4 Notch ligands and their receptors 
(Notch 1-4) are transmembrane proteins with extracellular domains that possess varying numbers 
of epidermal growth factor (EGF)-like repeats. The Notch-Delta signaling pathway was first 
described as being involved in communication between neighboring cells during development. 
Delta ligands were reported to have two different activities: Delta in one cell can bind and 
transactivate Notch signaling in a neighboring cell while inhibiting this signaling in its own cell 
(cis-inhibition).5,6 Notch activation requires three sequential proteolytic steps. The first 
proteolytic cleavage (the S1 cleavage) occurs intracellularly in the Notch ectodomain by a furin-
like convertase leading to the formation of an intramolecular heterodimeric cell-surface receptor 
which is protease-resistant in the absence of Notch ligands. Then, ligand binding to the 
extracellular domain of the Notch receptor initiates two sequential proteolytic cleavage events. 
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The first cleavage of these subsequent steps (the S2 cleavage) is catalyzed by the ADAM family 
metalloproteinases; the second (the S3 cleavage) is mediated by the transmembrane γ-secretase 
complex, resulting in the cytoplasmic release of Notch intracellular domain (NICD)7-9 which 
translocates into the nucleus where it interacts with members of the CSL family of DNA-binding 
transcription factors such as the recombining binding protein suppressor of hairless (RBP)-Jκ 
(also known as C-promoter binding factor-1, CBF1)10 as well as its co-activator proteins from 
the mastermind-like (MAML) family and histone acyltransferases.11,12 This leads to the 
formation of the short-lived NICD-CSL-MAML transcriptional activating complex which 
promotes the transcription of Notch-dependent target genes.13,14 In the absence of Notch 
signaling, RBP-Jκ acts as a repressor of transcription by binding to DNA in a sequence-specific 
manner.  
 
Non-canonical Notch signaling.  
The concept of non-canonical Notch signaling followed some in vitro studies where increased 
Notch 1 expression inhibited muscle cell differentiation but without up-regulating the expression 
of known CSL-dependent target genes, such as RBP-Jκ or hairy and enhancer of split 1 (HES-
1).15-16 Although canonical Notch ligands are predominantly responsible for Notch signaling in 
physiological and some pathological conditions, structurally unrelated non-canonical ligands 
have been identified and shown to be associated with cancers and inflammatory diseases.2,16-19  
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Figure 1. Notch receptors and ligands: canonical activation and signal transduction 
pathways.  There are four Notch receptors (Notch 1-4) and five ligands (Jagged 1, 2 and DLL-1, 
3, 4) in mammals. In Notch-expressing cells, Notch receptors need intracellular processing. First 
intramolecular proteolytic cleavage of the newly synthesized precursor receptors by furin-like 
convertases occurs within the Golgi apparatus, generating heterodimeric Notch receptors. Notch 
signaling is activated when ligand-expressing cells and Notch-expressing cells interact. The 
Notch heterodimer interaction with Notch ligands induces two subsequent proteolytic cleavages 
of the Notch receptor. One by ADAMs which liberates the extracellular domain followed by γ-
secretase within the transmembrane domain which results in the release of the intracellular Notch 
fragment, NICD. NICD translocates to the nucleus and binds to a nuclear protein complex, 
thereby displacing the co-repressor. This is accompanied by the recruitment of co-activator 
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proteins, including MAML1, which activates the transcription of Notch target genes. 
 
1.2 Regulation of Notch signaling.  
Notch signaling regulates the expression of target genes in a context- and cell-dependent manner. 
The dysregulation of Notch activation more commonly leads to oncogenesis; however, in some 
conditions Notch activation has tumor suppressive functions. Several studies have been 
conducted including genome-wide chromatin immunoprecipitation assays and sequencing to 
identify genes regulated by Notch.21,22 Well-studied transcriptional targets of Notch-RBP-Jk 
include Hes-1, the Notch-related ankyrin repeat protein (Nrarp), c-Myc and Deltex.23  
The existence of various specific Notch receptors and ligands allows fine tuning of the amplitude 
and duration of Notch activity to generate context- and tissue-specific signals. The downstream 
signaling is also controlled by post-transcriptional modifications including glycosylation, 
phosphorylation and ubiquitination. Notch is phosphorylated by the following three kinases: 
glycogen synthase kinase (GSK)-3β,24 cyclin-dependent kinase (CDK)8 25 and atypical protein 
kinase C (aPKC).26 In physiological conditions, Notch activation is transient, because NICD is 
phosphorylated after nuclear translocation, allowing interaction with a specific ubiquitin ligase 
(F-box and WD repeat domain-containing 7, FBW7) and ubiquitin-proteasome-mediated 
degradation.27,28 Thus, ubiquitin ligases are thought to function as tumor suppressors. Indeed, 
mutations in FBW7 and prolonged half-life of NICD were found in T-ALL patients resistant to 
γ-secretase inhibitors (GSIs)29,30 as well as in other solid tumors such as ovarian, breast and 
colorectal cancers.28,31 Furthermore, Notch signaling activation can also be regulated by 
ubiquitination of either the Notch receptor directly or its ligand expressed at the surface of the 
neighboring cell, thus promoting their endocytosis.32,33  
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2.  Notch signaling and oncogenesis. 
Notch signaling plays a crucial role in the regulation of cell proliferation, differentiation and 
apoptosis. Notch receptors and their ligands are overexpressed in many human cancers.34 For 
example, the Notch signaling pathway is involved in normal breast development, cell fate of 
normal breast stem cells, but also in the survival, proliferation and progression of breast cancer 
and breast cancer stem cells. Therefore, very complex and subtle pathways of control regulating 
Notch functions in cancer are required to design and develop therapeutics. 
 
2.1. Cell cycle and proliferation.  
The cell cycle comprises a series of coordinated events resulting in cell division. The cell cycle 
machinery regulates cell proliferation and cancer is known to be a disease of altered cell 
proliferation. It was demonstrated that cyclin D1 (CCND1) transcription and CDK2 activity were 
induced by Notch in a CSL-dependent manner.35 Genomic approaches demonstrated that 
hormone receptor-negative breast cancer cell lines express increased levels of Jagged 1 and 
identified CCND1 among Jagged 1-regulated genes.36 It was shown that Jagged 1 down-
regulation decreases direct binding of Notch to the CCND1 promoter, thus reducing CCND1 
expression and inhibiting cell cycle progression through the CCND1-dependant G1/S 
checkpoint. The proto-oncogene c-Myc, known to drive increased cell proliferation and to 
downregulate apoptosis, was identified as a direct downstream target of Notch 1.23 
 
2.2. Apoptosis.  
Cell death is decreased in cancer. Notch regulates cell death through extensive networks and 
signaling pathways of the cell cycle, cell growth and cell survival, including p53, nuclear factor-
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kappa B (NF-κB) and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin 
(mTOR).37 Activated Notch signaling increases the expression of anti-apoptotic genes like B-cell 
lymphoma-2 (Bcl-2) and the inhibitor of apoptosis gene family member, survivin.38,39 It was 
reported that Notch 1 function is required for tumor initiation via suppression of apoptosis 
through the regulation of p53 stability.40 In human breast cancer cell lines, increased RBP-JK–
dependent Notch signaling was sufficient to transform normal breast epithelial cells by a 
mechanism most likely involving suppression of apoptosis. Aberrant activation of Notch 1 and 
Notch 4 signaling led to the accumulation of NICD while attenuation of this signaling reverted 
the transformed phenotype of human breast cancer cell lines, suggesting that inhibition of Notch 
signaling may be a therapeutic strategy for this disease.41 Downregulation of Notch 3 expression 
using small hairpin RNA (shRNA) correlated with significant apoptosis and inhibition of 
proliferation of T-ALL cells.42 Recently, Notch 1 signaling has also been shown to control cell 
proliferation, cell death and differentiation in lung carcinoma.43 Interestingly, while Notch 
signaling has generally been associated with tumor growth, recent findings suggest that the effect 
may be context-dependent and determined by the type of Notch receptor-ligand interactions. 
Indeed, Notch 2 activation was shown to result in potent inhibitory signals and to induce 
apoptosis in human breast cancer xenografts.44 
 
2.3. Angiogenesis.  
Formation of new blood vessels is an important step for tumor growth and metastasis. Vascular 
endothelial growth factor (VEGF), one of the best-characterized inducer and key regulator of 
tumor angiogenesis, is induced by hypoxia-inducible signals in the tumor environment. In 
hypoxic conditions, Notch activity is also potentiated by the accumulation of hypoxia-inducible 
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factors (HIF)-1α and HIF-2α which synergize with Notch co-activator MAML1 to promote 
epithelial to mesenchymal trans-differentiation (EMT) and thereby metastasis. In line with these 
mechanisms, inhibition of either Notch or HIF results in reduced invasion and metastatic 
potential of tumor cells.45,46 Importantly, Notch signaling components are known to be expressed 
in endothelial cells and play an important role during vascular development.47-49 Notch ligands 
(in particular DLL) have been shown to be highly expressed in tumor vasculature and to 
positively correlate with VEGF and CD34 expression levels.50 Similarly, the level of Jagged 1 
expression was shown to correlate with tumor blood vessel content and associated with the 
progression of head and neck squamous cell carcinomas. 
 
2.4. Epithelial to mesenchymal trans-differentiation (EMT).  
EMT is a fundamental process during embryonic development whereby epithelial cells lose 
polarity and intercellular adhesion, adopt a mesenchymal phenotype and therefore acquire 
migratory properties. EMT is however pathologic in adult tissues leading to fibrosis and is often 
activated during cancer, contributing to tumor progression and metastasis.51,52 In epithelial and 
endothelial cells, Jagged 1/Notch activation results in morphologic and functional changes 
consistent with mesenchymal transformation.53 These changes include attenuation of many 
endothelial markers (endothelial cadherin (E-cadherin), endothelial nitric oxide synthase (eNOS) 
and platelet-endothelial cell adhesion molecule-1 (PECAM-1)) and upregulation of several 
mesenchymal markers (alpha smooth muscle actin (α-SMA), fibronectin, and platelet-derived 
growth factor (PDGF)-receptor)), increased migration, resistance to apoptosis and 
invasiveness.54,55 Moreover, the loss of the epithelial phenotype through EMT can promote the 
acquisition of a stem-like phenotype and drug resistance.56,57 By promoting EMT, Notch 
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signaling also regulates the formation of cancer stem cells (cells within a tumor that possess the 
capacity to self-renew and differentiate into the heterogeneous lineages of cancer cells that 
comprise the whole tumor) which were shown to be associated with tumor progression, 
metastasis and recurrence.58,59  
 
3. Notch as a tumor suppressor.  
Although Notch has been mostly implicated in oncogenic pathways, recent data suggest tumor 
suppressive functions in specific organs such as the liver, hematopoietic stem cells and the 
skin.13,60 In a mouse model of hepatocarcinoma (HCC),61 the inhibition of Notch signaling using 
the GSI DAPT62 (1, Table 1) resulted in accelerated cancer development, while enforced 
expression of NICD in HCC cells promoted cell cycle arrest in G2 phase and enhanced 
apoptosis. Investigating cohorts of HCC patients, the same authors observed better survival in 
patients with significantly higher expression of Notch1 and its target gene Hes1. In line with 
these data, Notch inhibition was reported to promote angiogenesis and growth of hepatic 
metastases.63 Whole-exome sequencing and gene copy number analyses performed in head and 
neck squamous cell carcinomas identified mutations in Notch1 predicted to truncate the gene 
product leading to inactivation.64 Notch ligands and receptors are also expressed in the skin 
where Notch signaling triggers pathways leading to keratinocyte growth arrest and 
differentiation as suggested by data showing that keratinocyte-specific deletion of Notch1 gene 
leads to marked epidermal hyperplasia.65 
 
4. Notch signaling in the kidney. 
Recent studies of renal diseases have yielded several candidate pathways for designing cell-
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targeted therapeutics, which include the Notch pathway.66-71 Within the kidney, injury to 
glomerular or tubular cells is the initiating cause of many acute and chronic diseases, leading to 
progressive dysfunction and end-stage renal disease. The glomerulus is the main filtration barrier 
that determines global kidney function. Inflammatory and non-inflammatory stress affects the 
glomerulus and leads to alterations in its structure, permeability and function, resulting in 
chronic kidney disease. Injury to the tubulo-interstitial tissue is a major cause of acute kidney 
disease, particularly in weakened hospitalized patients. Genetic studies performed in mice with 
conditional expression of the active Notch 1 protein showed massive glomerulosclerosis, leading 
ultimately to renal failure and death of the animals. Genetic deletion of Notch transcriptional 
binding partners or treatment with GSIs, preventing Notch activation and translocation to the 
nucleus, protected the animals from nephrotic syndrome. Thus, targeted pharmacologic 
inhibition of the Notch signaling pathway may prevent kidney damage in a variety of diseases.  
 
5. Notch signaling and fibrosis. 
Fibrosis is a non-specific terminal pathway following local inflammation and scarring. It is the 
hallmark of many chronic inflammatory diseases, as well as a predictor of progressive organ 
dysfunction.72,73 The pathogenesis of fibrosis involves an initial and probably repetitive tissue 
injury/inflammation that leads to abnormal tissue repair involving locally recruited inflammatory 
cells (in particular macrophages) and resident mesenchymal cells such as fibroblasts and 
myofibroblasts, resulting in thickening of the interstitial tissue and functional impairment. The 
increased number of (myo)fibroblasts could originate from either excessive proliferation and 
acquired resistance to physiological apoptosis or be the consequence of local EMT,74-76 all 
processes that can be regulated by Notch signaling. For example, in kidney diseases and after 
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kidney transplantation, tubulo-interstitial fibrosis (TIF) is considered as the final common 
pathway (whatever the primary lesion) leading to kidney dysfunction. TIF severity score is 
highly prognostic of organ survival.77,78 In experimental models, tubular epithelial cell-specific 
expression of active Notch 1 caused rapid development of TIF mainly through the process of 
EMT, whereas specific genetic deletion or pharmacologic inhibition using the GSI DBZ/ 
deshydroxyLY-41157566,79 (2, Table 2) ameliorated TIF.66 Transforming growth factor (TGF)-β 
is a growth factor secreted by immune cells recruited to inflamed/injured tissues contributing to 
tissue repair. In cultured human proximal tubular epithelial (HK-2) cells, TGF-β1 was shown to 
induce the expression of fibronectin (a stimulant and chemotactic agent for fibroblasts), as well 
as other factors involved in fibrosis and EMT including the Notch ligand Jagged 1.80 Overall, 
current data indicate that epithelial Notch signaling regulates interstitial fibrosis and its blockade 
could be a therapeutic strategy to prevent end organ diseases.  
 
6. Notch signaling and reproductive biology. 
Members of the Notch signaling pathway are expressed in mammalian ovaries and are important 
regulators of developmental pathways. Primary ovarian follicles cultured in vitro and treated 
with the GSIs 1 or L-658,45881,82 (3, Table 2) stopped their Notch-dependent development. 
Similarly, 1 or 3 inhibited proliferation of cultured primary granulosa cells. The Notch ligand 
DLL 4 is involved in normal luteal vasculature and Notch signaling plays an important role in 
regulating progesterone secretion in murine luteal cells. Murine luteal cells treated with 1 or 3 
demonstrated a decreased chorionic gonadotropin (hCG)-stimulated progesterone secretion, 
while overexpression of the intracellular domain of Notch 3 increased progesterone secretion.83,84  
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7. Therapeutic interventions targeting Notch. 
The understanding of the Notch signaling pathway has reasonably increased and its role in 
diverse pathological conditions has drawn attention for pharmacological interventions.85 Current 
strategies include disrupting the proteolytic cleavage/processing of Notch or inhibition of Notch-
ligand interactions. 
 
Potential points of intervention in the Notch pathway (Figure 2). 
As stated above, the Notch family of receptors comprises four members, Notch 1-4, with 
different, and sometimes antagonizing, roles in modulating cell and tissue functions, such as cell 
fate, proliferation, growth and differentiation. The four Notch receptors have different patterns of 
expression depending on the cell type and state of differentiation. Therefore, the exact choice of 
the therapeutic target is of utmost importance. Consequently, it is necessary to define whether 
pan-Notch or receptor-selective therapeutics are most appropriate.  
Notch receptors are large single-pass type I transmembrane glycoproteins, expressed as an 
heterodimer produced by proteolytic processing from a single chain O-glycosylated monomeric 
precursor (~300 kDa). The four mammalian Notch receptors have different sizes, Notch 1 is the 
largest and Notch 4 the smallest. All four receptors comprise three domains, the extracellular, the 
transmembrane and the intracellular domains. The extracellular N-terminal domains are the 
ligand binding part of the receptors and are constituted of several (29-36) EGF-like repeats and 
three disulfide bridges. The extracellular juxtamembrane domain regulates heterodimerization, 
maintaining the receptors in non-activated states. The transmembrane domain contains the γ-
secretase clavage site. The intracellular C-terminal domain extends from the inner cell membrane 
into the cytoplasm and contains both several regulatory elements, preventing ligand-independent 
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interactions, and the transcriptional activator domain. Following binding of one of the Notch 
receptor ligands a conformational change in the receptor occurs, allowing the initiation of the 
activation of the Notch intracellular pathways and transcriptional program.  
The vertebrate Notch ligands are represented by two families of single-pass type I 
transmembrane-inserted proteins, DLL-1, 3 and 4 and Jagged 1 and 2, with intracellular and 
extracellular domains. The extracellular domain is the binding domain comprising 6-10 EGF-like 
repeats, Jagged ligands bearing an additional cysteine-rich domain. The ligands for Notch 
receptors are expressed by cells different from the cells expressing the receptors. Cell-cell 
contact allows interaction between Notch receptors and their ligands, mediated by the EGF-like 
repeats of both receptors and ligands. This interaction initiates a conformational change (the 
“pull”) in the Notch receptors, exposing a cleavage site (the S2 site) for ADAM 
metalloproteinases, leaving approximately 12 amino acids protruding on the extracellular 
membrane. The remaining transmembrane protein is then subjected to a further proteolytic 
processing, mediated by the membrane-inserted aspartyl protease γ-secretase at amino acid 
Val1744. This proteolytic step results in the release of NICD from the membrane into the 
cytoplasm and its translocation into the nucleus. NICD forms a transcriptional activation 
complex in the nucleus, leading to increased expression of specific genes, including c-Myc, p21, 
CCND1 (cell cycle progression), Bcl-2 (inhibition of apotosis) as well as genes of the Hes and 
Hey families (mediating cell fate). Then the NICD is phosphorylated in the nucleus and marked 
for degradation by the proteasome.85 
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Figure 2. Biosynthesis of the Notch receptors and potential control of their activation. 
Schematic representation of the Notch activation pathways in cells and the potential points of 
control for the modulation of Notch-dependent functions.  
 
Below, we will review various attempts to modulate the Notch signaling pathway for therapeutic 
intervention in human diseases, in particular the drugs which have been evaluated in clinical 
trials. 
 
Where is it possible to act to modulate the functions of the Notch signaling pathway?  
1: regulating the activation of the genes and translation of the Notch receptors and ligands.  
For blocking (or activating) the Notch genes several approaches have been attempted using gene 
silencing by shRNAs, siRNAs, miRNAs, or modification of histone chaperones acting as gene 
silencing. However, to the best of our knowledge, these tools have been used only in in vitro cell 
1: activation of the Notch receptors genes 
2: processing of the Notch precursors 
3: interaction with receptor ligands 
4: inhibition of ADAM/TACE 
5: inhibition of γ-secretase 
6: blockage of nuclear gene responses 
17 
 
or animal experimental models. While this is very useful to define the role of Notch in 
physiological and pathological situations, or to validate experimental tools, no attempts have 
been made to exploit these tools in the clinic. Notch signaling can also be modulated downstream 
of Notch receptor activation by other pathways, such as the PI3/Akt, GSK3 or EGFR pathways, 
which may also be used to indirectly modify the Notch signaling pathway.  
 
2: inhibiting the processing of the precursors of the Notch receptors by furin-like proteases, 
glycosylation pathways and exit from the ER/Golgi.  
Glycosylation pathways and processing of precursor proteins by furin-like convertases are 
fundamental pathways in the homeostasis of all tissues and cells and in the processing of many 
secreted proteins. Thus, very specific and selective tools are required to target Notch 
glycosylation or processing by furins in defined diseased cells. To the best of our knowledge, the 
role of these pathways has only been determined in in vitro cellular or animal experimental 
models. No attempts at targeting Notch glycosylation have been made in the clinic. A few furin 
inhibitors have been developed (see below) and evaluated in animal models not involving Notch 
processing. These compounds may also be of interest in the control of the Notch signaling 
pathway, if they can be rendered specific and selective for defined cells. 
Furins (PACE, paired basic amino acid cleaving enzyme, EC 3.4.31.75) are a family of calcium-
dependent serine endoproteases biosynthesized as inactive proenzymes which need self-mediated 
intra-chain cleavage to become enzymatically active. Furins belong to the subtilisin-like 
proprotein convertase family. The members of this family process latent precursor proteins into 
their biologically active products,86,87 including TGF-β1 precursor, pro-β-secretase, membrane 
type-1 matrix metalloproteinase, the HIV envelope polyprotein precursor gp160 to gp120 and 
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gp41, and Notch precursors. Furins have also been involved in tumor progression. Furins are 
mainly located within the Golgi/trans-Golgi secretory pathway where they cleave other proteins 
downstream of a di-basic amino acid target sequence (Arg/Lys-Arg) into their mature/active 
forms. Inhibitors of furins have been explored as therapeutic agents for treating anthrax 
infection. Soluble furins can be inhibited by EGTA, α1-antitrypsin and polyarginine compounds, 
as well as by a few synthetic molecules. 
The catalytic mechanism of enzymes of the serine protease family involves a catalytic triad 
located in the active site of the enzyme. The triad is a coordinated structure consisting of three 
essential amino acids, one histidine, one serine and one aspartic acid. In the catalytic mechanism 
several intermediates are generated, including a covalent acyl-enzyme intermediate. The released 
pro-fragments frequently act as inhibitors of the enzyme. Furin inhibitors have been developed, 
they include:  poly-arginine peptides, α1-antitrypsin, decanoyl-Arg-Val-Lys-Arg-chloromethyl 
ketone (4, furin inhibitor I), CCG-8294 (5) (Figure 3).88,89 Furin inhibitor I is a selective, 
irreversible and cell-permeable competitive inhibitor of proprotein convertases, including 
furin/SPC1 (Ki = ~1 nM), SPC2/PC2 (Ki = 0.36 nM), SPC3/PC1/PC3 (Ki = 2.0 nM), 
SPC4/PACE4 (Ki = 3.6 nM), SPC6/PC5/PC6, and SPC7/LPC/PC7/PC8 (Ki = 0.12 nM). 
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Figure 3: Examples of furin inhibitors. 
 
Very recently, in a furin-unrelated approach for controling the processing of protein precursors in 
intracellular organelles, FLI-0690 (6, Table 4) has been shown to be an inhibitor of Notch 
signaling (IC50 = 2.3 μM), which also reduces amyloid-β (Aβ) secretion. 6 acts upstream of α-
secretase and β-secretase cleavage, inhibiting endoplasmic reticulum (ER) export and thus 
disrupting intracellular trafficking and processing of Notch and general secretion at a step before 
exit from the ER. Therefore, 6 is the first small molecule acting at such an early stage in the 
secretory traffic. This inhibition is accompanied by a tubule-to-sheet morphological transition of 
the ER. 6 does not act on the cytoskeleton, but causes a complete disruption of the Golgi in a 
manner different from that of Brefeldin A or Golgicide A. These data highlight the power of 
phenotypic screening for investigating central cellular signaling pathways. Obviously such an 
approach would need further validation to evaluate its clinical interest and potential and again 
very tight mechanisms of specificity and selectivity of delivery to the target cells.  
 
3: controlling the interaction between the Notch receptors and their ligands. 
Notch signaling can also be blocked more specifically by using monoclonal antibodies (mAbs) 
against individual Notch ligands or receptors overexpressed in diseases.91-94 Inhibition of Notch 
signaling using a mAb targeting DLL-4 resulted in reduced tumor growth mainly by controlling 
angiogenesis as DLL-4 expression in endothelial cells is dynamically regulated by VEGF. These 
findings also indicated that DLL4-mediated Notch signaling is predominantly restricted to the 
vascular compartment and that targeting DLL-4 may have limited adverse impact on other cells 
including intestinal cell differentiation. The selective blockade of Notch 1 activation using a 
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mAb against the human Notch 1 ligand-binding domain (EGF-repeats 11 to 15) decreased breast 
cancer stem-like cells proliferation and induced apoptosis.94,95   
The binding of a ligand to a Notch receptor induces a conformational change of the receptor 
which is the result of a “pull” force on the ligand to be internalized by endocytosis, exposing a 
site on the receptor for proteolysis by ADAMs. Conversly, the agonist 256A-13 (structure not 
disclosed) can induce the proteolytic cleavage of Notch 396 by mimicking the effects of ligand 
binding to Notch. Antagonists able to bind to the Notch receptors without inducing the “pull” 
and the subsequent proteolytic step have also been developed. 
 
4: inhibiting Notch cleavage by the ADAMs. 
ADAMs, and in general metalloproteinases, have been the targets of several campaigns of drug 
development and clinical evaluation. Several families of enzyme-selective inhibitors have been 
designed and may present some interest in the context of the control of Notch activation. 
However, to the best of our knowledge, none of them has reached clinical trials for Notch 
blockade, while some of them have been evaluated in pre-clinical Notch experimental models. 
Members of the ADAM metalloproteinases are cell surface proteins with a unique structure 
possessing both potential adhesion and protease domains. Sheddases, a generic name for the 
ADAM metalloproteinases, function primarily to cleave membrane proteins at the cell surface, 
releasing soluble ectodomains of their protein substrates. Although a single sheddase may “shed” 
a variety of substrates, multiple sheddases can cleave the same substrate resulting in different 
consequences. Whereas the exact enzymatic mechanism of ADAMs has not been thoroughly 
investigated, their active sites are comparable to those of well studied zinc-proteases such as 
carboxypeptidase A and thermolysin. Therefore, it is proposed that ADAMs utilize similar 
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mechanisms as these enzymes. In zinc-proteases, the key catalytic elements consist in a Zn2+ ion, 
two histidines and a glutamic acid. The water molecule is hydrogen-bonded to another glutamic 
acid in a relay system with either a serine or a histidine of the enzyme. The proposed mechanism 
begins with deprotonation of the water molecule by the glutamic acid. The resultant hydroxide 
initiates a nucleophillic attack on a carbonyl carbon of the peptide backbone, producing a 
tetrahedral intermediate, leading to the first transition state and the formation of the tetrahedral 
intermediate. Following the formation of the transition state, the leaving group is protonated and 
the peptide bond is cleaved. 
ADAM metalloproteinase domain 17 (ADAM17/TACE, tumor necrosis factor-α-converting 
enzyme, EC 3.4.24.86), is a 70-kDa protein involved in the shedding of tumor necrosis factor 
alpha (TNF-α) at the surface of cells and in the membrane of the trans-Golgi network. ADAM17 
releases other membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and 
enzymes, or regulates the MAP kinase signaling pathway by controling the shedding of the 
EGFR ligand amphiregulin. ADAM17 also hydrolyses the full-length amyloid precursor protein 
(APP) to the soluble N-terminal fragment. Functional ADAM17 is ubiquitously expressed in the 
human colon, and is overexpressed in digestive tract diseases.97-99 The ADAM17 inhibitor TAPI-
1100 (7, TNF-alpha protease inhibitor 1, Figure 4) is an inhibitor of matrix metalloproteinases 
(MMPs), including ADAM17/TACE which blocks the shedding of cell surface proteins with an 
IC50 = 8.1 µM for TNF-α.  
ADAM metalloproteinase domain 10 (ADAM10, CDw156 or CD156c, EC 3.4.24.81) has a 
broad specificity for peptide hydrolysis, including TNF-α, ephrin, APP, CD44, HER2 and 
Notch.101,102  The ADAM10 inhibitor GI254023X103 (8, Figure 4) is potent and selective as it 
displays over 100-fold higher potency for ADAM10 compared to ADAM17 (IC50 = 5.3 nM for 
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ADAM10 versus 541 nM for ADAM17/TACE) and blocks the constitutive shedding of cell 
surface proteins in cells. In combination with low doses of the anti-HER2 herceptin, selective 
ADAM10 inhibitors decrease proliferation of HER2-overexpressing tumor cells. 
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Figure 4: Examples of ADAMs inhibitors. 
 
5: inhibiting the S3 cleavage by the γ-secretase. 
The use of GSIs has been the most explored way of controlling Notch activation. The search for 
GSIs started with the aim of inhibiting the processing of APP by γ-secretase in Alzheimer’s 
disease (AD).104-106 AD is characterized by the loss of neuronal functions, and the presence of 
extracellular plaques of Aβ (Aβ1-40 and Aβ1-42) aggregates and intercellular neurofibrillary 
tangles of phosphorylated tau protein, which have been postulated to be responsible for the 
development of AD. The Aβ aggregates are produced by the sequential action of two aspartyl 
proteases, the β-secretase (BACE) and the γ-secretase on APP. The γ-secretase cell membrane-
inserted protease complex has the capacity to cleave the APP transmembrane domain inside the 
cell membrane. BACE and γ-secretase are found throughout the secretory pathway and at the cell 
surface. Therefore, these two aspartyl proteases are obvious targets to develop therapeutic 
interventions for AD, and inhibitors for these two proteases have been developed and clinically 
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evaluated.107,108 In the context of AD,105,106 pre-clinical and clinical evaluations of GSIs revealed 
unwanted side-effects attributed to the inhibition of Notch processing.  
The enzyme γ-secretase is a large protease complex composed of four transmembrane proteins: 
three support proteins, Pen-2 (presenilin enhancer protein-2), Aph-1 (anterior pharynx-defective-
1, of which 3 isoforms exist) and Nct (nycastrin) and the catalytic subunit presenilin (PS, EC 
3.4.23.-), of which two isoforms exist, PS-1 and PS-2. Thus, several γ-secretase complexes may 
be assembled, with slightly different substrate specificities, but all four proteins are obligatory 
for the enzymatic activity of γ-secretase. In humans, the PSEN-1 gene is located on chromosome 
14 and the PSEN2 gene on chromosome 1. PS-1 and PS-2 share high sequence homology and 
have nine transmembrane domains, with a cytosolic amino-terminus and a luminal carboxy-
terminus. PS-1 and PS-2 are the catalytic part of the γ-secretase complex, the two catalytic 
aspartic acids being located in the membrane lipid bilayer in the transmembrane domains 6 and 
7, close to each other in a water containing cavity.109,110 The presence of these two close aspartic 
acid residues and the water molecule is an important feature of the complex, since the catalytic 
mechanism of aspartyl proteases (which include renin, HIV protease, cathepsin D and BACE) 
requires the presence of a water molecule activated by two carboxylates. This activated water 
molecule directly attacks the peptide bond, producing a transition-state intermediate, without the 
formation of a covalent intermediate. Substrates of γ-secretase first bind to Nct, then the catalytic 
subunits of the γ-secretase complex perform an intra-membrane hydrolysis.111 However, very 
recently and in contrast to previous studies, it was shown that the substrate transmembrane 
domain drives its interaction with γ-secretase. The γ-secretase component Nct sterically blocks 
substrates with large ectodomains from interacting with γ-secretase, providing the mechanism by 
which γ-secretase selectively recruits short ectodomain substrates. γ-secretase-substrate binding 
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is driven by an apparent tight-binding interaction derived from substrate transmembrane 
domain.112 γ-secretase cleaves single-pass transmembrane proteins and has over 100 identified 
and postulated substrates, which include Notch. The γ-secretase complex activates Notch by 
hydrolyzing a peptide bond of the Notch protein at an intra-membrane site, allowing the cleaved 
NICD to migrate to the nucleus where it activates responsive genes.113 The intra-membrane 
activity of the γ-secretase has also been involved in the release from the membrane of other 
biologically relevant membrane proteins involved in normal and pathological processes, 
including insulin-like growth factor or sorting receptors.114,115 Therefore, for selective therapy, it 
is mandatory to achieve only localized inhibition of this activity, thus protecting the other 
functions of this enzyme complex and the normal physiological functions of the Notch pathway 
in particular.  
More than thousands34,109 of different types of GSIs have been designed, synthesized and 
evaluated: competitive active site binders, non/uncompetitive substrate docking site binders, 
alternative site binders. These include various peptides isosteres, benzazepines, sulfonamides and 
others. Many of them are orally active, have low nanomolar IC50 values and several of them have 
been evaluated in clinical trials. They can be either transition-state analogs (targeting the active 
site of the enzyme like the substrates) or non-transition-state analogs (targeting the active site of 
the enzyme or binding sites different of the enzyme active site), benzazepines, sulfone analogs or 
tetralin imidazoles (Tables 1 and 2).  
 
6: blocking the transcriptional response induced by the NICD. 
For blocking (or activating) the transcriptional functions of Notch several approaches can be 
attempted using gene silencing or decoy proteins of the components of the transcriptional 
25 
 
complex. However, to the best of our knowledge, these tools have been used only in in vitro 
cellular or animal experimental models. No attempts have yet been made to test these in the 
clinic.  
 
8.  Preclinical and clinical trials aimed at controlling the Notch signaling pathway in 
diseases. 
Current approaches in preclinical and clinical trials116 include inhibiting the proteolytic 
processing of the Notch receptor and/or interfering with the ligand-receptor interaction. 
Auxillary proteins, such as glycosylases, kinases or ligases, involved in the Notch pathway also 
offer new possibilities of control. In addition, some biotechnological tools have been developed, 
for example recent patents related to Notch signaling have been published which include: 
transfection of cells with the NICD for anti-viral purposes (Academy of Military Medical 
Sciences, CN103386137) or Notch 3 fusion protein as decoy for cancer (Columbia University, 
SG193873).117 
 
GSI-based therapeutics. 
As Notch ligand-receptor binding interaction triggers intramembranous cleavage of the Notch 
receptors by the γ-secretase complex, targeting this complex using pharmacological inhibitors is 
the most studied approach to effectively inhibit the production of NICD and the transcription of 
Notch target genes.106 Following encouraging results obtained using human cancer cell lines in 
vitro together with xenograft experimental models,118-121 ongoing clinical trials are now 
investigating the safety and potential efficacy of GSIs, alone or in combination with other drugs, 
in various types and stages of cancer or inflammation. During the development and evaluation of 
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GSIs for AD, undesirable side-effects were observed which were attributed to the poor 
selectivity of these GSIs and their interference with the processing of AD-unrelated protein 
substrates by γ-secretase, in particular the components of the Notch signaling pathway. The off-
target side-effects observed for GSIs included gastrointestinal toxicity,122 cognitive worsening 
and an increased risk for some cancers. These observations resulted in the termination of clinical 
trials of, for example, semagasestat/LY-450139123,124 (9, Table 1) in phase III. Therefore, in 
some situations, GSIs are required to possess an increased selectivity for Notch as compared to 
the myriad of other γ-secretase substrates. 
In cancer, and in particular cancers of the immune cells such as acute myeloid leukemia (Notch 
silenced) or T-ALL (Notch constitutively activated), the Notch signaling pathways have been 
shown to have both pro-tumoral (oncogenic) and tumor suppressive functions. These effects 
depend on the cell type, the stage and grade of the tumor and the cellular context, including the 
role of the stromal environment of the tumor (angiogenesis, immune response, fibrosis), as well 
as the presence of mutations in the different components of Notch and its associated cellular 
pathways, such as apoptotic and proliferative responses. Therefore, under some situations the 
Notch pathway needs to be therapeutically blocked, whereas in others it should either be induced 
or activated. The choice of which of the Notch receptor and ligand must be modulated also needs 
to be defined, and presently it is not always clear which factors dictate this choice. Several GSIs 
have been evaluated in human clinical trials (Table 1).  
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Table 1. γ-secretase inhibitors of clinical interest for therapeutic blockade of the Notch 
pathway in cancer.  
 
code/name      chemical  structure        company         clinical trials      [references]     
 
______________________________________________________________________________ 
 
1 DAPT              Eli Lilly      GSI most widely       62,105 
    used experimentally  
 
 
 
______________________________________________________________________________ 
 
9 LY-450139           Eli Lilly        phase I       123,124 
semagacestat       (development stopped  
in 2010 in phase III  
         for AD) 
  
______________________________________________________________________________ 
 
10 BMS-906024            Bristol-Myers Squibb phase II      125   
  
 
 
 
 
______________________________________________________________________________ 
 
11 PF-030840 1     Pfizer  phase II      126-128 
 
                  
 
 
 
_____________________________________________________________________________ 
 
12 RO4929097        Hoffmann-LaRoche phase I/II      119,129 
                
 
 
 
_____________________________________________________________________________ 
N
N
O
N
H
NH2
F
F F
F
F
FO
O
 
NH
F
F
H
N
N N H
NO
 
HN
H
N
H
N F
F
F
F F
O
O O
 
H
N
N
H
F
F
O
O
O
O
 
H
N
N
H
OH
O
O
N
O  
28 
 
13 MK-0752                Merck   phase  I/II      108,130,131 
            
 
 
 
 
 
_________________________________________________________________________________ 
 
14 BMS-708163    Bristol-Myers Squibb phase I          132-134  
avagacestat        (development  
          stopped in 2012  
in phase II for AD) 
                       
           
 
______________________________________________________________________________ 
 
15 GSI 136                   Wyeth / Pfizer phase I            135,136 
            
 
 
______________________________________________________________________________ 
 
16 GSI-953             Wyeth  phase I       137    
begacestat     (tested in normal         
    volunteers)   
        
 
______________________________________________________________________________ 
 
17 LY-900009            Eli Lilly  phase I       138    
         (phase 1 stopped  
         for adverse events)            
 
 
 
______________________________________________________________________________ 
 
18 BMS-299897                      Bristol-Myers Squibb phase I/II      139,140 
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These GSIs are all able to inhibit γ-secretase with low nanomolar efficacy. However, to evaluate 
their efficacy, very different biological models have been used, either cell-based, cell-free or 
animal models, and no standardized protocols have been used and no reference molecule for 
comparison has been included in the assays. For some of them, only APP processing has been 
determined. Therefore, directly comparing their potency toward Notch inhibition is at best 
problematic. Thus, the IC50 values, when available, provided below must be used with caution. 
162,105 is a non-transition state analog GSI and is the compound most widely evaluated in 
experimental models. 1 causes a reduction in Aβ levels in human primary neuronal cell cultures 
with IC50 values = 115-200 nM. 1 blocks Notch signaling in a cell-based assay measuring the 
activation of the Notch pathway reporter gene with an IC50 = 500 nM. As an inhibitor of Notch, 1 
has also been used in the study of autoimmune and lymphoproliferative diseases. 9123,124 is an 
orally available GSI (Aβ: IC50 = 10.9-12.1 nM; Notch: IC50 = 14.1 nM) that was developed as a 
candidate therapeutic drug against AD (IDENTITY trial), which failed in phase III trials. BMS-
906024 (10, Table 1)125 is a new pan-Notch GSI disclosed by Bristol-Myers Squibb at the 2013 
Spring ACS meeting. The structure is one of a set patented in 2012, and is currently being 
studied in Phase I clinical trials, both alone and in combination with other drugs to treat breast, 
lung, colon cancers and leukemia. PF-03084014 (11, Table 1)126-128 is a non-transition state GSI 
(Aβ: IC50 = 1.2 nM, cell-based assay; IC50 = 6.2 nM, cell-free assay) with potential antitumor 
activity, inhibiting tumor cell proliferation and survival, inducing apoptosis of tumor cells that 
overexpress Notch and in xenografts models, reducing endogenous NICD levels and 
downregulating the Notch target genes Hes-1 and c-Myc in T-ALL cell lines via cell cycle arrest. 
Broad antitumor efficacy at well-tolerated dose levels was observed in six Notch-dependent 
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animal models. Further studies of 11-induced gastrointestinal toxicity identified an intermittent 
dosing schedule that limited body weight loss, while maintaining antitumor efficacy. 
Glucorticoids administration abrogated 11-induced gastrointestinal toxicity without 
compromising the protective effect. Collectively, current results show that inhibition of Notch 
signaling by 11 while minimizing gastrointestinal toxicity128 represents a promising approach for 
development of therapies in Notch receptor-dependent cancers. This compound is being 
investigated in phase I clinical trials for the treatment of T-ALL as well as for advanced solid 
tumors. RO4929097 (12, Table 1)119,129 is a GSI displaying an IC50 = 4 nM in a cell-free assay. 
12 inhibits cellular processing of Aβ40 and Notch with EC50 = 14 nM and 5 nM, respectively, in 
a Notch cell-based reporter assay. The potency of 12 in cell-free and cell-based assays displays 
>100-fold selectivity with respect to 75 other proteins of various types including receptors, ion 
channels, and enzymes (CEREP panel). It was shown that 12 blocked Notch processing in 
human non-small cell lung carcinoma cells and decreased the expression of the Notch 
transcriptional target genes. However, 12 only modestly inhibited the growth of cells in a dose-
dependent manner (1 μM of 12 induced 10-20 % cell growth inhibition depending on the cells). 
12 increased T-cell activation and shifted cytokines towards a Th1 profile. In nude mice bearing 
A549 lung tumor cell xenografts, oral gavage of 3 to 60 mg/kg 12 once daily or twice daily for 
either 7, 14, or 21 days resulted in significant tumor growth inhibition (ranging from 66% to 
91%) compared with vehicle-treated animals. Inhibition of tumor growth remained prolonged 
and sustained up to 34 days post-treatment. 12 led to reduced expression of genes associated with 
angiogenesis in A549 xenografts. In contrast, the 12-resistant H460a xenograft models displayed 
little change in expression of these genes, underscoring the in vivo anti-angiogenesis mechanism 
of action of 12. For IL-6 and IL-8 overexpressing tumors, 12 no longer impacted angiogenesis or 
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the infiltration of tumor associated fibroblasts. MK-0752 (13, Table 1)130,131 is a non-transition 
state analog GSI which reduces Aβ40 with an IC50 = 5 nM in human cells. 13 also inhibits Notch 
cleavage to NICD and its subsequent nuclear translocation in vitro. It is presently in Phase I/II 
clinical trials for cancer. BMS-708163/avagacestat (14, Table 1)132-134 is a potent, allosteric, 
orally bioavailable GSI inhibiting Aβ formation with a IC50 = 0.3 nM and Notch activation with 
an IC50 = 58 nM. As Notch inhibition caused side effects that forced the termination of the 
previous clinically evaluated compound 9, the drug-development program presently aims to 
achieve a greater selectivity between APP and Notch inhibition. 14 binds directly to the PS-1 N-
terminal fragment and that binding can be challenged by other pan-GSIs, but not by γ-secretase 
modulators. Furthermore, 14 blocks the binding of four different active site-directed GSI 
photoaffinity probes. 14 reduces cerebrospinal fluid Aβ levels without causing Notch-related 
toxicity in rats and dogs, however, not all publications agrees on that.123 Gastrointestinal and 
dermatological manifestations such as diarrhea, nausea, vomiting, rash, and itching skin are the 
main side effects. GSI 136 (15, Table 1)135,136 was developed by Wyeth (now a subsidiary of 
Pfizer) for AD treatment and evaluated in phase I clinical trials to determine its safety and 
tolerability in healthy subjects. The evaluation of this drug has been extended to other diseases. 
However, no information about the outcomes of the trials is presently available. GSI-
953/begacestat (16, Table 1)137 is an orally active GSI which selectively inhibits the cleavage of 
APP with an IC50 = 14.8 nM and is 16-fold more selective for APP over Notch (Notch: IC50 = 
208.5 nM). LY-900009 (17, Table 1)138 is a selective orally available small-molecule GSI 
inhibiting Notch activation with an IC50 = 0.27 nM; 17 was evaluated in clinical trials for the 
treatment of cancer. The study was terminated in Phase I due to adverse events, including 
diarrhea, vomiting, nausea, fatigue, anorexia, hypophosphatemia and skin rash of different 
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grades. As a GSI, 17, also decreases plasma levels of Aβ in a dose-dependent manner. BMS-
299897 (18, Table 1)139,140 is an orally active GSI with an IC50 = 12 nM for Aβ production.  
 
Several other GSIs (Table 2) have been designed and evaluated only in experimental and 
preclinical settings, including a series of bicyclic sulfonamide pyrazoles141 (structures not 
disclosed) (IC50 APP = 0.4 nM; IC50 Notch = 36 nM). These compounds may represent the next 
series of GSIs with clinical potential. 
 
Table 2. γ-secretase inhibitors not (yet) evaluated in clinical trials for therapeutic blockade 
of the Notch pathway in human diseases or evaluated for other diseases. 
 
code         structure    IC50          comments [references] 
____________________________________________________________________________ 
 
2 DBZ          Aβ: 2.6 nM;  benzazepine              66,79                         
(deshydroxy-         Notch: 2.9 nM  
LY-411575)                                                                               
YO-01027 
 
_____________________________________________________________________________________________ 
 
3 L-658,458         Aβ:17 nM (cell-free) transition state       81,82 
      Aβ:115-200 nM (cell) analog    
                
                
 
 
 
______________________________________________________________________________ 
 
19 LY-411575   Aβ: 0.08 nM;  benzazepine        142,143  
   Notch: 0.39 nM       induces apoptosis  
in Kaposi’s sarcoma cells 
         promotes neural and  
intestinal goblet  
cell differentiation  
____________________________________________________________________________ 
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20 MRK-003         non-transition        120,144-146  
         state analog     
sulfonamide  
         inhibits Notch3 
          
 
______________________________________________________________________________ 
 
21 MRK-560     Aβ: 65 nM  sulfonamide       147,148 
         selective for Aβ      
         over Notch   
 
 
 
 
______________________________________________________________________________ 
 
22 LY-3039478 Notch: 0.41 nM benzazepine      149,150                                                                                                                                                                                                                  
_______________________________________________________________________ 
 
GSI-based clinical trials. 
According to the role of the Notch pathway in cancer, several phase I clinical trials were initiated 
(Table 3, data obtained from ClinicalTrials.gov) in adult patients with advanced hematological 
and solid tumors to determine maximum tolerated dose for further phase II trials and assess 
safety, pharmacokinetics and potential clinical activity. GSIs were tested either as single agents 
or in combination with standard cancer chemotherapy regimen. From these early clinical studies, 
tolerability and toxicity have been acceptable, in both single or combined therapies,151,152 with 
side-effects (mainly gastrointestinal disorders) comparable, but not worse, than standard 
chemotherapeutics. The main side-effects encountered were gastrointestinal disorders. Some 
encouraging clinical benefits were observed, associated with a modest decrease of Notch gene 
signature. However, since only phase I or II studies are presently underway, it will be necessary 
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to wait for the results of phase III trials of large multicenter cohorts of cancer patients to 
determine possible clinical benefits of GSIs.  
 
Table 3. Ongoing and completed clinical trials of GSIs in cancer.  
NCT 
identifier 
Ph
ase 
Therapeutic agent Status Sponsor/Collaborators Tumor type 
NCT01292655  I 10 Recruiting Bristol-Myers Squibb  Advanced or metastatic solid 
tumors 
NCT01653470 I 10 + chemotherapy 
regimens 
Recruiting Bristol-Myers Squibb  Advanced or metastatic solid 
tumors 
NCT01363817  I 10 + dexamethasone Recruiting Bristol-Myers Squibb  T-ALL or T-cell 
lymphoblastic lymphoma 
NCT02137564 II 11 Active AIDS Malignancy Clinical  
Trials Consortium National 
Cancer Institute (NCI), 
The EMMES Corporation 
AIDS-related Kaposi sarcoma 
NCT01238133 I 12 + carboplatin  
+ paclitaxel 
Active NCI Stage II or III triple-negative 
breast cancer 
NCT01238133  12 + cediranib maleate Completed NCI Advanced solid tumors 
 
NCT01154452 I/II 12 + vismodegib Active NCI Advanced or metastatic 
sarcoma 
NCT01981551 II 11 Ongoing NCI Desmoid tumors/aggressive 
fibromatosis 
NCT01196416 I/II 12 + cisplatin  
+ vinblastine  
+ temozolomide 
Ongoing NCI Recurrent or metastatic 
melanoma 
NCT01088763 I 12 + dexamethasone Terminated NCI Relapsed or refractory solid 
tumors, CNS tumors, 
lymphomas or T-ALL 
NCT01145456 I 12 + gemcitabine  Completed NCI Advanced solid tumors 
 
NCT01096355 I 12 Completed NCI Metastatic or non-removable 
solid malignancies 
NCT01232829 II 12 Completed NCI Metastatic pancreatic cancer 
 
NCT00756717   13 + tamoxifen or 
letrozole 
Ongoing Loyola University;  
Merck Sharp & Dohme Corp. 
Breast cancer 
NCT01193881                 I 12 + erlotinib Ongoing NCI Stage IV or recurrent non-
small cell lung cancer 
NCT01270438 II 12 + FOLFOX regimen 
+ bevacizumab 
Withdrawn NCI Metastatic colorectal cancer 
NCT01149356  I 12 + exemestane Terminated NCI Advanced or metastatic breast 
cancer 
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NCT01175343 II 12 Ongoing NCI Recurrent and/or metastatic 
epithelial ovarian cancer, 
fallopian tube cancer, or 
primary peritoneal cancer 
NCT01122901  II 12 Ongoing NCI Recurrent or progressive 
glioblastoma 
NCT01071564 I 12 + vismodegib Terminated NCI Advanced breast cancer 
NCT01218620  I 12 + chemotherapeutics Completed NCI Advanced solid tumors 
NCT01119599 I 12 + temozolomide  
+ radiation therapy 
Ongoing NCI Newly diagnosed malignant 
glioma 
NCT00803894  I 13 Completed Merck Sharp & Dohme Corp Healthy male volunteers to 
identify biomarkers for Cancer 
or Alzheimer’s disease 
NCT01295632  I 13 + ridaforolimus  Ongoing Merck Sharp & Dohme Corp  Advanced cancer 
NCT00572182  I 13 Terminated 
 
Pediatric Brain Tumor 
Consortium and NCI 
CNS cancer 
NCT00645333  I/II 13 + docetaxel Completed University of Michigan 
Cancer Center 
Advanced or metastatic breast 
cancer 
NCT01243762  I 13 + dalotuzumab Terminated Merck Sharp & Dohme Corp Advanced cancer 
 
NCT00106145  I 13 Completed Merck Sharp & Dohme Corp Metastatic or locally advanced 
breast cancer and other 
advanced solid tumors 
NCT00828646  I 14 Completed Bristol-Myers Squibb Healthy volunteers 
 
NCT01198535 I 12 + cetuximab Terminated NCI Metastatic colorectal cancer 
NCT00100152  I 13 Terminated Merck Sharp & Dohme Corp T-ALL 
NCT01208441  I 12 + letrozole Terminated NCI Stage II/III hormone receptor-
positive breast cancer 
NCT01269411 I 12 Terminated NCI Recurrent malignant glioma 
 
NCT01200810  II 12 + bicalutamide Terminated NCI Prostate cancer 
 
NCT01070927  II 12 Completed Hoffmann-La Roche Recurrent or refractory non-
small cell lung cancer  
NCT00878189  I 11 Ongoing Pfizer  Advanced solid tumors, T-
ALL 
NCT01057030  I 14 Completed Bristol-Myers Squibb  
 
Healthy young male subjects 
to assess safety  
NCT01189240 I/II 12 + bevacizumab Ongoing NCI Progressive or recurrent 
malignant glioma 
NCT01120275  II 12 Ongoing NCI Advanced melanoma 
 
NCT00719394 I 15 Completed Wyeth/Pfizer Healthy  male volunteers to 
assess safety  
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Non-GSI-based therapeutics. 
Non-GSI small molecule inhibitors have also been evaluated in preclinical settings, which 
include γ-secretase modulators,153 like E2012/HY10016154 (23, Table 4), JLK6155 (24, Table 4), 
and non-steroidal anti-inflammatory drugs (NSAID) like flurbiprofen/flurizan156 (25, Table 4) or 
the endoplasmic reticulum-exporting inhibitor molecule 690. Their mode of biological action is 
presently not well understood, but γ-secretase modulators and non-steroidal anti-inflammatory 
drugs are hypothesized to modulate the enzyme hydrolytic step, thus altering its cleavage site 
preference, depending on the γ-secretase complex expressed. However, these drugs have high 
IC50 values and seem to be more efficient in inhibiting APP processing than the other potential γ-
secretase substrates, including Notch. A deeper understanding of their modes of action may be 
helpful in designing substrate-specific inhibitors of γ-secretase. 
  
NCT01216787  II 12 Withdrawn NCI Stage IIIB, IIIC or IV 
melanoma 
NCT01192763 I 12 Terminated NCI Pancreatic cancer 
 
NCT01193868  II 12 Completed NCI Advanced non-small cell lung 
cancer 
NCT01158274 I 12 + capecitabine Completed NCI Refractory solid tumors 
 
NCT01151449  II 12 Ongoing NCI Advanced, metastatic or 
recurrent triple negative 
invasive breast carcinoma 
NCT01198184 I 12 + temsirolimus Completed NCI Advanced solid tumors 
NCT01217411  I/II 12 + radiation therapy  
+ stereotactic 
radiosurgery 
Terminated NCI Brain metastases from breast 
cancer 
NCT01141569  II 12 Completed NCI Advanced renal cell carcinoma 
 
NCT01116687  II 12 Completed NCI Metastatic colorectal cancer 
 
NCT01236586  I 12 Withdrawn NCI Children relapsed/refractory 
solid or CNS tumors, 
lymphoma or T-ALL 
NCT01098344  I 13 + gemcitabine  Completed Cancer Research UK Stage III and IV pancreatic 
cancer 
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Table 4. Synthetic Notch antagonists with non-GSI mode of actions. 
 
code         structure       IC50              comments  reference 
______________________________________________________________________________ 
 
6 FLI-06       Notch: 2.3 µM      inhibits ER exporting         90  
             
 
 
 
 
______________________________________________________________________________ 
 
23 E2012        Aβ:0.15-5.6 µM benzazepine                  154 
        no effects on    
Notch processing;  
inhibits 3β-hydroxysterol  
Δ24-reductase in the  
cholesterol biosynthesis 
 
_____________________________________________________________________________ 
 
24 JLK6       Aβ:30 µM              isocoumarin           155 
  no effects on Notch  
   cleavage    
_____________________________________________________________________________ 
 
25 Flurizan                             Aβ active 100 µM nonsteroidal anti-        156 
Flurbiprofen          inflammatory drug  
    (NSAID) 
           inhibits γ-secretase 
 
_____________________________________________________________________________ 
 
 
More recently, bioengineered antibodies or antibody-drug conjugates157,158 targeting either Notch 
receptors, Notch ligands, Notch receptor-ligand interactions or γ-secretase itself have also been 
developed. Some of them are presently evaluated in clinical trials (Table 5).  
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Table 5. Ongoing and completed clinical trials of antibodies targeting Notch signaling. 
 
 
Clinical trials evaluating ADAM inhibitors. 
Therapeutic options other than targeting the γ-secretase-Notch pathway involve targeting the 
NCT 
identifier 
Ph
ase 
Therapeutic agent Status Sponsor/Collaborators Tumor type 
NCT01577745 I MEDI0639 
(anti-DLL-4 mAb) 
Recruiting MedImmune LLC Advanced solid tumors 
NCT00744562 I Demcizumab 
(anti-DLL-4 mAb) 
Completed OncoMed Pharmaceuticals, 
Inc. 
Solid tumors 
NCT00871559 I REGN421 
(SAR153192) 
Completed Regeneron Pharmaceuticals 
and Sanofi 
Advanced solid malignancies 
NCT02298387 I OMP-305B83 
anti-DLL-4/VEGF 
bispecific mAb 
Recruiting OncoMed Pharmaceuticals, 
Inc. 
Solid tumors 
NCT01189942 I Demcizumab +  
folinic acid + 
fluorouracil + 
irinotecan 
Ongoing OncoMed Pharmaceuticals, 
Inc. and Novotech (Australia) 
Pty Limited 
Metastatic colorectal cancer 
NCT01189968  I Demcizumab + 
carboplatin + 
pemetrexed  
Recruiting OncoMed Pharmaceuticals, 
Inc. and Novotech (Australia) 
Pty Limited 
Non-small cell lung cancer  
NCT01189929  I Demcizumab + 
abraxane® + 
gemcitabine 
Recruiting OncoMed Pharmaceuticals, 
Inc. and Novotech (Australia) 
Pty Limited 
Locally advanced or 
metastatic pancreatic cancer 
NCT01952249  I/II Demcizumab + 
paclitaxel 
Recruiting OncoMed Pharmaceuticals, 
Inc. 
Ovarian, primary peritoneal  
or fallopian tube cancer 
NCT01703572  I OMP-52M51  
(anti-Notch 1 mAb) 
Recruiting OncoMed Pharmaceuticals, 
Inc. and GlaxoSmithKline 
Lymphoid malignancies 
NCT01778439 I OMP-52M51 Recruiting OncoMed Pharmaceuticals, 
Inc. and GlaxoSmithKline 
Solid tumors 
NCT01647828  I/II OMP-59R5 
anti-Notch 2/3 mAb 
+ gemcitabine  
+ Nab-paclitaxel 
Recruiting OncoMed Pharmaceuticals, 
Inc. 
Pancreatic cancer 
NCT01859741  I/II OMP-59R5 +  
etoposide + cisplatin 
or carboplatin 
Recruiting OncoMed Pharmaceuticals, 
Inc. 
Small cell lung cancer 
NCT01277146  I OMP-59R5 Ongoing OncoMed Pharmaceuticals, 
Inc. 
Solid tumors 
NCT01013597  II LBH589  
(panobinostat, a 
selective HDAC 
inhibitor) 
Ongoing University of Wisconsin, 
Madison and Novartis 
Pharmaceuticals 
Metastatic thyroid cancer 
NCT00985946  II LBH589 Ongoing University of Wisconsin, 
Madison and Novartis 
Pharmaceuticals 
Neuroendocrine tumors 
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other Notch-activating enzymes, either the furins or the ADAM10 and ADAM17 proteases. We 
do not believe that targeting the intracellular multipurpose furins is a viable option. Targeting the 
cell-surface ADAMs may be more interesting.116,159 The matrix metalloproteinases (MMPs) have 
been linked to cancer progression many years ago and their potential values as therapeutic targets 
for cancer has been examined in numerous clinical trials, unfortunately with mostly negative 
results. These previous trials used broad-spectrum inhibitors, which was hypothesized to be the 
cause of failure. More selective inhibitors for the ADAM10 or ADAM17 have been designed 
and developed,160 and are presently evaluated for clinical use in a specific cancer, diffuse large B 
cell lymphoma, as well as in inflammatory diseases or diabetic nephropathy (Table 6).  
 
Table 6. Clinical trials evaluating ADAM inhibitors.  
 
Presently only very few reports evaluating ADAM inhibition on the Notch pathway have been 
published. A recent study,161 comparing ADAM17 inhibition and 1-mediated γ-secretase 
inhibition has shown an advantage for ADAM inhibition in a model of renal carcinoma; 
unfortunately, these authors used Marimastat as an ADAM inhibitor, which can also inhibit other 
MMPs in addition to ADAM17. To the best of our knowledge, no clinical trials evaluating such 
inhibitors in the Notch context are underway, whereas ADAM inhibitors are clinically tested for 
Compounds NCT identifier 
Phase Therapeutic 
Agent 
Status Sponsor/Collaborators Tumor type 
 ADAM17 
inhibitor NCT02141451  I/II INCB7839 Recruiting 
Masonic Cancer Center, 
University of Minnesota 
Diffuse large B 
cell lymphoma  
ADAM10/17 
inhibitor NCT00312780 II XL784 Completed Symphony Evolution, Inc.  
Diabetic 
nephropathy 
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cancer and inflammatory diseases. Whether in the long-term a role for regulating the Notch 
pathway using these inhibitors will come to light requires more detailed analysis of these trials. 
 
9. The problem of selectivity/specificity of γ-secretase inhibition. 
The major challenge in targeting the Notch pathway for therapeutic purposes is both selectivity 
and specificity of the drugs aimed at controlling Notch functions, both in cancer and in 
inflammatory diseases. The use of drugs designed and developed for inhibiting the γ-secretase 
has been the first therapeutic attempt to control the Notch signaling pathway. However, clinical 
trials with these drugs have generally resulted in toxicities and side-effects, which were 
attributed in the inhibition of hydrolysis of AD-unrelated substrates of this protease, including 
Notch. Therefore, more tissue-, cell- and Notch-selective therapeutic tools must be designed for 
the treatment of cancer or inflammatory diseases. 
In a recent approach,162 using experimental rodent models of inflammatory and profibrotic 
kidney diseases and toward selective targeting of GSIs, we have developed prodrug strategies, as 
potentially selective, precise and efficient systems. To achieve disease selectivity of GSIs we 
have designed and evaluated pro-drugs of the GSI RO5016025162 (26, Figure 5), a close analog 
of 12, as substrates for enzymatic activities specifically expressed in diseased kidneys. Previous 
data had shown that the activities of the peptidases aminopeptidase A (APA, substrate: α-Glu-
XX), γ-glutamyltranspeptidase (γ-GT, substrate: γ-Glu-XX) and γ-glutamylcyclotransferase (γ-
GCT, substrate: N-Ac-γ-Glu-XX) are highly increased in tissues from patients and rodent 
experimental models of human diseases, including kidney diseases, suggesting that these 
enzymes may be used for drug targeting purposes. We therefore developed γ-secretase inhibitor-
based prodrugs as potential substrates for γ-GT, γ-GCT and APA (Figure 5) and in vitro and in 
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vivo evaluation demonstrated the interest of using γ-Glu prodrugs but not α-Glu prodrugs of 
GSIs. 
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Figure  5. Chemical structure of a protease-targeted pro-drug of a γ-secretase inhibitor. 
 
10. Conclusions and Perspectives 
The canonical Notch pathway with 4 receptors and 5 ligands plays critical roles in context-
dependent tissue and cell-fate determination. In cancer, this pathway has a determining impact 
on tumor behavior and response to therapy. Considering the role of Notch signaling in the 
pathogenesis of different cancers, Notch proteins in general function as oncogenes; however, 
tumor suppressive functions have also been reported in certain cell types, highlighting the 
context-dependent role of Notch signaling. Presently, no Notch-targeting therapeutics are FDA-
approved, but multiple therapeutics are under clinical evaluation for cancer, including GSIs 
synthetic or non-GSI biological molecules, such as bioengineered antibodies or antagonists.162,163 
No large multicenter phase III clinical trial has yet been initiated, therefore it is premature to 
foresee the future of these therapeutics, but the tolerability profile has been shown to be 
acceptable (at least in the context of cancer) in early phase I/II clinical trials.  
However, due to the potential side-effects of these drugs, more cell and tissue-selective and 
amino acid sequences 
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specific inhibitors are needed. The most studied target of the Notch pathway, the activating 
enzyme γ-secretase, is an intra-membrane protein complex with multiple potential and actual 
substrates identified. Non-selective inhibition of γ-secretase by the initial GSIs has been shown 
to result in serious side-effects mainly due to interfering with the normal functions of Notch as 
well as the other substrates of γ-secretase. A deeper understanding of the enzymatic mechanisms 
and mode of binding of its substrates and modulators163-168 may lead to the development of more 
cell- and tissue-selective and specific Notch inhibitors for the therapy of cancer or inflammatory 
diseases. GSIs able to inhibit Notch cleavage with slightly improved selectivity over the other 
biological substrates of this protease are being developed and must be evaluated in clinical trials. 
A second attempt has been to develop antibodies to inhibit the binding of ligands to their Notch 
receptors or to inhibit the γ-secretase enzyme activity. These antibodies are also presently under 
clinical evaluation, mainly for cancer.169 A different approach involves the development of 
targeting prodrugs of GSIs, as potentially selective, precise and efficient systems, using over-
expressed diseased tissue-selective molecules, thus increasing local drug distribution and 
decreasing toxicity and off-target effects.162 A yet unexplored (to the best of our knowledge) 
therapeutic approach involves the use of nanoparticles loaded with Notch antagonistic drugs. In 
most normal blood vessels, the gaps between vascular cells are too small to allow for the passage 
of nanoparticles. Both cancer and inflammatory diseases result in impaired vascular functions 
and leaky blood vessels, the enhanced permeability and retention (EPR) effect, allowing the 
passage of nanoparticles across the disease-associated vascular wall into the organs, and their 
retention in the organ. Other possibilities involve targeting the other Notch-activating enzymes, 
either the furin-like proteases or the ADAM10 and ADAM17 proteases. We do not believe that 
targeting the intracellular multipurpose furins is a viable option. Targeting the cell-surface 
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ADAMs may be an option to consider for future therapeutic developments in inflammatory and 
oncologic diseases, however with problems of selectivity and specificity of ADAM inhibition for 
the diseased tissues comparable to γ-secretase inhibition. 
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